Format

Send to

Choose Destination
Expert Rev Neurother. 2008 Aug;8(8):1193-201. doi: 10.1586/14737175.8.8.1193.

Cell-based therapy in ischemic stroke.

Author information

1
Department of Neurology, Medical College of Georgia, Augusta, GA 30912, USA. dhess@mail.mcg.edu

Abstract

Cell-based therapy for stroke represents a third wave of therapeutics for stroke and one focused on restorative processes with a longer time window of opportunity than neuroprotective therapies. An early time window, within the first week after stroke, is an opportunity for intravenously delivered bone marrow and perinatally derived cells that can home to areas of tissue injury and target brain remodeling. Allogeneic cells will likely be the most scalable and commercially viable product. Later time windows, months after stroke, may be opportunities for intracerebral transplantation of neuronally differentiated cell types. An integrated approach of cell-based therapy with early-phase clinical trials and continued preclinical work with focus on mechanisms of action is needed.

PMID:
18671663
PMCID:
PMC2753686
DOI:
10.1586/14737175.8.8.1193
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center